Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

AMD is shipping more desktop chips to keep up with the demand as the Ryzen 9800X3D remains hard to find in stock.